Imugene (IUGNF) Price & Analysis

Compare

39 Followers

IUGNF Stock Chart & Stats

$0.18

>-$0.01(-3.57%)

At close: Jan 08 4:00 PM EST

$0.18

>-$0.01(-3.57%)

Day’s Range― - ―

52-Week Range$0.03 - $1.47

Previous CloseN/A

Volume3.00K

Average Volume (3M)16.95K

Market Cap

$52.66M

Enterprise Value$64.84M

Total Cash (Recent Filing)$14.14M

Total Debt (Recent Filing)$5.02M

Price to Earnings (P/E)―

Beta0.50

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding321,516,020

10 Day Avg. Volume11,247

30 Day Avg. Volume16,948

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.15

Price to Sales (P/S)21.99

P/FCF Ratio-1.07

Enterprise Value/Market Cap1.23

Enterprise Value/Revenue20.66

Enterprise Value/Gross Profit23.25

Enterprise Value/Ebitda-1.10

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.12

Revenue Forecast (FY)$3.43M

Bulls Say, Bears Say

Bulls Say

Pipeline Breadth In Immuno-oncologyImugene’s pipeline spans multiple modalities (oncolytic virus CF33 programs and vaccine candidates PD1-Vaxx, HER-Vaxx). That program breadth diversifies technical risk across mechanisms, increases partnering/licensing optionality and sustains long-term clinical upside if trials advance.

Conservative Capital StructureA low debt-to-equity ratio and moderate equity financing indicate limited leverage. This conservative balance sheet preserves financial flexibility to fund R&D or secure partnerships, lowers interest obligations, and reduces short-term solvency pressure while clinical development continues.

Free Cash Flow MetricA positive free cash flow to net income ratio suggests that, despite accounting losses, the company can generate periods where free cash flow outpaces net income. This indicates potential cash-generation capacity that can mitigate funding needs under improving operating conditions.

Bears Say

Severe Revenue DeclineA reported revenue decline of -338.95% reflects a collapse in reported sales activity and highlights the absence of meaningful commercial revenue. This increases dependency on external financing or partnerships to fund multi-year clinical programs, raising execution risk.

Persistent UnprofitabilityDeeply negative profitability metrics show the company is not generating operating profits. Persistent losses raise the likelihood of equity dilution from future capital raises, constrain reinvestment into trials, and limit internal resources for scaling development or commercialization.

Negative Operating Cash FlowNegative operating cash flow indicates the business currently consumes cash to run operations. Continued operational cash outflows erode reserves, force reliance on external funding, and increase timing and execution risk for costly, multi-year clinical trials and regulatory programs.

Imugene News

Imugene posts high response rates for azer-cel in early CAR T-naïve lymphoma trial

The latest update is out from Imugene ( ($AU:IMU) ). Imugene reported strong early efficacy data from the...

4h ago

Imugene Seeks Trading Halt Ahead of Capital Raising Announcement

Imugene ( ($AU:IMU) ) has issued an update. Imugene has requested an immediate trading halt in its securities...

5h ago

Imugene’s VAXINIA Trial Termination: What the Latest Clinical Update Means for IUGNF Investors

Imugene Ltd ($IUGNF) announced an update on their ongoing clinical study. The phase I MAST study tests Imugene...

3d ago

IUGNF

Imugene’s OASIS Trial Termination: What It Means for IUGNF Investors

Imugene Ltd ($IUGNF) announced an update on their ongoing clinical study. The OASIS study, officially titled “A Phase...

3d ago

IUGNF

Imugene to Showcase Lead CAR T Therapy at Major TD Cowen Health Care Conference

The latest update is out from Imugene ( ($AU:IMU) ). Imugene Limited, a clinical-stage immuno-oncology company, will present...

11d ago

Imugene secures A$2.7m R&D tax refund to advance cancer pipeline

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has received an A$2.74 million research and development...

13d ago

Imugene Narrows Half-Year Loss but Net Tangible Assets Fall

Imugene ( ($AU:IMU) ) has issued an announcement. Imugene reported a net loss attributable to members of $37.8...

13d ago

Imugene Sets March 2026 Expiry for ASX-Listed Options

Imugene ( ($AU:IMU) ) has shared an update. Imugene Limited has notified holders of its listed options on...

14d ago

Imugene Issues Small Tranche of Unquoted Options in Capital Structure Update

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has notified the market of the issue of...

18d ago

Imugene Issues 1.7 Million New Shares on Convertible Note Conversion

The latest update is out from Imugene ( ($AU:IMU) ). Imugene Limited has issued 1,736,111 fully paid ordinary...

1M ago

IUGNF FAQ

What was Imugene’s price range in the past 12 months?

Imugene lowest stock price was $0.03 and its highest was $1.47 in the past 12 months.

What is Imugene’s market cap?

Imugene’s market cap is $52.66M.

When is Imugene’s upcoming earnings report date?

Imugene’s upcoming earnings report date is Aug 28, 2026 which is in 171 days.

How were Imugene’s earnings last quarter?

Imugene released its earnings results on Feb 25, 2026. The company reported -$0.091 earnings per share for the quarter, beating the consensus estimate of -$0.237 by $0.146.

Is Imugene overvalued?

According to Wall Street analysts Imugene’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Imugene pay dividends?

Imugene does not currently pay dividends.

What is Imugene’s EPS estimate?

Imugene’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Imugene have?

Imugene has 321,516,020 shares outstanding.

What happened to Imugene’s price movement after its last earnings report?

Imugene reported an EPS of -$0.091 in its last earnings report, beating expectations of -$0.237. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Imugene?

Currently, no hedge funds are holding shares in IUGNF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imugene Stock Smart Score

Underperform

Fundamentals

Return on Equity

-134.65%

Trailing 12-Months

Asset Growth

-39.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Imugene

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.